ESH Meeting Highlights 2005

 
 
 
‹‹‹ Click on the dates to see the daily articles!
 
 
 
 
June 20

hypertensive diabetics
Manidipine performs better than amlodipine in hypertensive diabetics with early nephropathy patients

 
Manidipine did not affect sympathetic activity, measured as an increase in pulse pressure and heart rate, in a small study of 91 patients with type 2 diabetes, hypertension, and incipient nephropathy, compared to amlodipine.

Cardiovascular Remodeling and Hypertension: Its Effects and Clinical Value


Prof. E. Agabiti Rosei
 
See the video

Prof. Enrico Agabiti Rosei delivered a lecture on the cardiovascular remodeling and its prognostic value in hypertension during the 15th European Meeting of Hypertension. He spent some time with ESHonline during the meeting to talk about this important aspect of hypertension and its treatment.

CV events reduced with more intense treatment in high risk patients

 
The INTEROUT study presented by Dr. Zhi-Min Hin from Shanghai showed again that in high-risk Chinese patients more intensified antihypertensive treatment reduces cardiovascular (CV) morbidity and mortality. The FEVER trial, also presented at the 15th European Meeting on Hypertension, showed that the addition of felodopine in patients, significantly reduced CV events and cancer.

Intensified therapy, compared to routine therapy, reduced the primary endpoint by 78% (p<0.0001), total mortality by 64% (p<0.0001), and stroke (fatal and nonfatal) by 72% (p<0.001). The primary endpoint was the composite of stroke (fatal and nonfatal), MI (fatal and nonfatal), and other CV death.

At 4.5 years, SBP was 132 mmHg in the intensified group and 150 mmHg in the routine therapy group, and DBP was less than 90 mmHg in both groups.

There were 381 patients in the routine therapy group and 382 in the intensified treatment group. The mean age was 65 years, BMI 24, SBP 175 mmHg, DBP 98 mmHg. Eleven percent of the routine group and 9% of the intensified group had a previous stroke. Intensified treatment was initiated with either ACE inhibitor, beta-blocker, CCB, or a diuretic, and then drugs added from other classes as needed to lower BP to <140/90 mmHg.

 
Legal
The materials presented here were prepared by independent authors under the editorial supervision of ESHonline, and do not represent a publication of the European Society of Hypertension. These materials and the related activity are not sanctioned by the European Society of Hypertension and do not constitute an official part of that conference. These materials may discuss uses and dosages for therapeutic products that have not been approved by the nationals and internationals Laws. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity. Copyright © ESHonline.org.